Susquehanna International Group, LLP Morphic Holding, Inc. Transaction History

Susquehanna International Group, LLP

  • $560 Billion
  • Q3 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024
BUY
$26.12 - $34.07 $418,781 - $546,244
16,033 Added 22.94%
85,932 $2.93 Million
Q1 2024

May 07, 2024
BUY
$26.64 - $40.31 $1.48 Million - $2.24 Million
55,582 Added 388.22%
69,899 $2.46 Million
Q4 2023

Feb 14, 2024
BUY
$19.95 - $31.0 $285,624 - $443,827
14,317 New
14,317 $413,000
Q2 2023

Aug 11, 2023
SELL
$34.33 - $62.11 $370,455 - $670,229
-10,791 Reduced 19.07%
45,809 $2.63 Million
Q1 2023

May 16, 2023
BUY
$26.01 - $48.69 $1.19 Million - $2.22 Million
45,674 Added 418.03%
56,600 $2.13 Million
Q4 2022

Feb 14, 2023
SELL
$24.14 - $30.37 $545,419 - $686,179
-22,594 Reduced 67.4%
10,926 $292,000
Q3 2022

Nov 14, 2022
BUY
$22.23 - $33.37 $745,149 - $1.12 Million
33,520 New
33,520 $949,000
Q2 2022

Aug 15, 2022
SELL
$19.74 - $43.01 $333,921 - $727,557
-16,916 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$36.25 - $52.02 $124,265 - $178,324
-3,428 Reduced 16.85%
16,916 $679,000
Q4 2021

Feb 14, 2022
BUY
$43.27 - $65.72 $40,414 - $61,382
934 Added 4.81%
20,344 $964,000
Q3 2021

Nov 15, 2021
BUY
$53.61 - $67.5 $449,895 - $566,460
8,392 Added 76.17%
19,410 $1.1 Million
Q2 2021

Aug 11, 2021
BUY
$45.13 - $64.99 $497,242 - $716,059
11,018 New
11,018 $632,000

Others Institutions Holding MORF

# of Institutions
8
Shares Held
4.7M
Call Options Held
0
Put Options Held
0
View Full List

About Morphic Holding, Inc.

MORF Quotes by TradingView
  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email